期刊文献+

丹参联合缬沙坦对早期慢性肾衰的疗效评价 被引量:11

Clinical efficacy of salvia combined with Valsartan in the treatment of early chronic renal failure
下载PDF
导出
摘要 目的探讨丹参联合缬沙坦治疗早期慢性肾衰的临床疗效。方法将60例早期慢性肾衰患者随机分为对照组与观察组,每组各30例。两组患者均给予慢性肾衰常规治疗,给予对照组患者缬沙坦口服,观察组患者在缬沙坦口服基础上给予丹参注射液静点,疗程为4周。比较两组肾功能、尿微量白蛋白(ALB)、24h尿微量白蛋白排泄率(UAER)、尿微球蛋白(β-MG)、血脂及血流变学指标的改变。结果两组血清肌酐(Cr)比较差异无统计学意义(P>0.05);治疗后观察组ALB、UAER、β-MG显著低于对照组(P<0.05);血流变学指标显著优于对照组(P<0.05);血TG、TC显著低于对照组(P<0.05)。结论丹参联合缬沙坦治疗早期慢性肾衰可显著减少患者尿蛋白,改善血流变学及血脂,延缓肾功能不全的发展。 Objective To explore the clinical effect of salvia combined with Valsartan in the treatment of ear- ly chronic renal failure. Methods Sixty patients with early chronic renal failure were randomly divided into the con- trol group and the study group, with 30 patients in each group. Patients in the control group received oral administra- tion of Valsartan based on routine treatment, while those in the study group received salvia quiescent point plus intra- venous drip of Valsartan based on routine treatment. Renal function, ALB, UAER, β-MG, blood lipid and blood rheolo- gy indexes were compared between the two groups. Results There were no statistically significant difference in the levels of Cr between the two groups (P〉0.05); The levels of ALB, UAER and β-MG were significantly lower in the study group than the control group (P〈0.05); Blood theology indexes in the study group were significantly better than that in the control group (P〈0.05); The levels of serum TG and TC in the study group were significantly lower than that in the control group (P〈0.05). Conclusion For patients with early chronic renal failure, salvia combined with Valsartan can greatly decrease urine protein, improve blood lipid and blood theology indexes, and delay the progress of renal failure.
作者 王怀庆
出处 《海南医学》 CAS 2012年第12期43-45,共3页 Hainan Medical Journal
关键词 肾功能不全 丹参 缬沙坦 Renal failure Salvia Valsartan
  • 相关文献

参考文献5

二级参考文献31

  • 1孙宁玲.血管紧张素受体拮抗剂在高血压治疗中的作用及地位[J].中华医学杂志,2005,85(25):1732-1733. 被引量:34
  • 2谌承志,肖琳玲,邓万俊.血管紧张素转换酶抑制剂与血管紧张素Ⅱ受体拮抗剂预防心律失常的研究进展[J].心血管病学进展,2006,27(4):437-440. 被引量:4
  • 3赵林双,向光大,乐岭,侯洁,徐琳,蒋文.血管紧张素Ⅱ受体拮抗剂对糖尿病肾病蛋白尿影响的临床观察[J].中国医师杂志,2007,9(4):484-486. 被引量:5
  • 4[1]Schmidt B,Drexler H,Schieffer B.Therapeutic effects of angiotensin (AT1) receptor antagonists:potential contribution of mechanisms other than AT1 receptor blockade[J].Am J Cardiovasc Drugs,2004,4:361-368.
  • 5[3]FOGARI R,MUGELLINI A,ZOPPI A,et al.Efficacy of losartan,valsartan,and telmisartan in patients with mild to moderate hypertension[J].Curr Ther Res,2002,63:1-14.
  • 6[4]Fogari R,Mugellini A,Zoppi A,et al.A double-blind crossover study of the antihypertensive efficacy of angiotenin Ⅱ-receptor antagonists and their activation of the renin-angiotensin system[J].Curr Ther Res Clin E,2000,61:669-679.
  • 7[5]Julius S,Kjeldsen SE,WeberM,et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial[J].Lancet,2004,363:2022-2031.
  • 8[6]Staessen JA,Richart T.Sum and substance in the Jikei Heart Study[J].Lancet,2007,369:1407-1408.
  • 9[7]Mochizuki S,Dahlǒf B,Shimizu M,et el.Valsartan in a Japanese population with hypertension and other cardiovascular disease(Jikei Heart Study):a randomised,open-label.blinded endpoint morbidity-mortality study[J].Lancet,2007,369:1431-1439.
  • 10[8]Cohn JN,Toghoni G.A randomiaed trial of the angiotersin-recepptor blocker valsartan Chronic heart faifure[J].N Engl Med,2001,345:1667-1675.

共引文献13

同被引文献166

引证文献11

二级引证文献185

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部